Docosahexaenoic acid endocannabinoid epoxide derivative compositions

ABSTRACT

The present disclosure provides novel compounds derived from docosahexaenoic acid endocamabinoid epoxides having anti-cancer, anti-inflammatory, anti-platelet aggregation and anti-angiogenic properties. Methods of synthesizing and using the compositions are also provided.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of and priority to U.S. ProvisionalApplication No. 62/560,719, filed on Sep. 20, 2017, the content of whichis incorporated by reference herein in its entirety, and priority towhich is hereby claimed.

BACKGROUND

Endocannabinoid epoxides (eCBs) have been found in various rat organsand have been shown to be anti-inflammatory, anti-angiogenic and toreduce platelet aggregation. However, eCBs have two hydrolysablefunctional groups which make them less stable in the human body. First,soluble epoxide hydrolases (sEH) hydrolyze the epoxide to inactive diolcompounds and fatty acid amide hydrolase (FAAH) hydrolyzes the amidefunctional group to free acid, thereby reducing the molecule'sbiological activity. Derivatives of eCBs with improved biologicalstability are needed to make them better candidates for therapeutics.

SUMMARY

The present disclosure relates to novel endocannabinoid epoxides,pharmaceutical compositions thereof, and methods of use thereof.

In one aspect, the present disclosure provides a compound or acomposition of formula (I), or a pharmaceutically acceptable saltthereof,

wherein,

one of L¹, L², L³, L⁴, L⁵, and L⁶ is

and the others of L¹, L², L³, L⁴, L⁵, and L⁶

is 3- to 6-membered ring containing at least one heteroatom selectedfrom the group consisting of oxygen, nitrogen, and sulfur;

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x1), -G¹, or—C₁₋₆alkylene-G¹;

G¹ is C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl, heteroaryl, orheterocycle, wherein G¹ is optionally substituted with 1, 2, 3, or 4R^(x1);

R² is C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x2), -G², or—C₁₋₆alkylene-G²;

G² is C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl, heteroaryl, orheterocycle, wherein G² is optionally substituted with 1, 2, 3, or 4R^(x2);

R^(x1) and R^(x2) at each occurrence are independently cyano, —OH,—OC₁₋₄alkyl, —OC(O)C₁₋₄ alkyl, —NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl)₂,—NHC(O)C₁₋₄alkyl, or —N(C₁₋₄alkyl)C(O)C₁₋₄alkyl; provided that R² is not—CH₂CH₂OH when is

In another aspect, the present disclosure provides a pharmaceuticalcomposition comprising a compound of formula (I), or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier.

In another aspect, the present disclosure provides a use of a compoundor composition of formula (I), or a pharmaceutically acceptable saltthereof, for treating a disease, condition, or disorder in a subject.For example, the compounds or compositions disclosed herein may be usedfor treating cancer, reducing inflammation, reducing plateletaggregation, reducing angiogenesis, inducing vasoconstriction orvasodilation.

In another aspect, the present disclosure provides a use of a compoundor composition of formula (I), or a pharmaceutically acceptable saltthereof, for manufacturing a medicament for treating a disease,condition, or disorder in a subject. For example, the compounds orcompositions disclosed herein may be used for manufacturing a medicamentfor treating cancer, reducing inflammation, reducing plateletaggregation, reducing angiogenesis, inducing vasoconstriction orvasodilation.

In yet another aspect, the present disclosure provides a method oftreating cancer comprising administering to a subject in need thereof atherapeutically effective amount of a compound of formula (I), or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.

In yet another aspect, the present disclosure provides a method ofreducing inflammation comprising administering to a subject in needthereof a therapeutically effective amount of a compound of formula (I),or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.

In yet another aspect, the present disclosure provides a method ofreducing platelet aggregation comprising administering to a subject inneed thereof a therapeutically effective amount of a compound of formula(I), or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.

In yet another aspect, the present disclosure provides a method ofreducing angiogenesis comprising administering to a subject in needthereof a therapeutically effective amount of a compound of formula (I),or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.

In yet another aspect, the present disclosure provides a method ofinducing vasoconstriction or vasodilation comprising administering to asubject in need thereof a therapeutically effective amount of a compoundof formula (I), or a pharmaceutically acceptable salt thereof, or apharmaceutical composition thereof.

Other aspects will become apparent by consideration of the detaileddescription and accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The features, objects and advantages other than those set forth abovewill become more readily apparent when consideration is given to thedetailed description below. Such detailed description makes reference tothe following drawings.

FIG. 1A shows various isomers of EDP-EAs.

FIG. 1B shows modifications at the carboxylic acid group for allcorresponding epoxide derivatives, i.e. 19,20-EDP-n-propylamine,19,20-EDP-isopropylamide through to 4,5-EDP-n-propylamine,4,5-EDP-isopropylamide.

FIG. 1C shows aziridine derivatives of 4,5-EDP through 19,20-EDP forthree amide groups.

FIG. 1D shows thiirane derivatives of 4,5-EDP through 19,20-EDP forthree amide groups.

FIG. 2 shows apoptosis by all three amine derivatives in threeosteosarcoma cell lines HOS (non-metastatic) and 143B and MG63(metastatic) as compared to endogenous compound 10,11-EDPEA and vehiclecontrol: control (solid); 10,11-EDP-EA (checkered); 10,11-EDP-NA (dots);10-11-EDP-IA (horizontal stripes); 10,11-EDP-CA (vertical stripes).

FIG. 3A shows the anti-migratory property of amino derivatives as aratio to the control in osteosarcoma cell line HOS (non-metastatic).

FIG. 3B shows the anti-migratory property of amino derivatives as aratio to the control in osteosarcoma cell line 143B

FIG. 3C shows the anti-migratory property of amino derivatives as aratio to the control in osteosarcoma cell line MG63.

FIG. 4 Top panel shows reduction of nitrite by all EDP-EA isomers.Bottom panel shows reduction in 11-6 and nitrite in a dose dependentmanner by 19,20-EDP-EA.

FIG. 5A shows binding of all EDP-EA derivatives to CNR1.

FIG. 5B shows binding of all EDP-EA derivatives to CNR2.

FIG. 6 shows susceptibility to FAAH hydrolysis of 10,11-DHEA epoxidesand its amide derivatives.

FIG. 7 shows the anti-migratory property of test compounds as a ratio tothe control in osteosarcoma cell line HOS (non-metastatic), osteosarcomacell line 143B, and osteosarcoma cell line MG63: control (solid);10,11-EDP-EA (checkered); 10,11-EDP-NA (dots); 10-11-EDP-IA (horizontalstripes); 10,11-EDP-CA (vertical stripes).

FIG. 8 shows prevention of angiogenesis in HUVEC cells with 10,11-EDP-EAand its analogs as described in Example 9.

FIG. 9 shows the mass spectrum for the product of Scheme 2B.

FIG. 10 shows the 1H NMR spectrum for the product of Scheme 3B.

The compounds, compositions, and methods will be described more fullyhereinafter with reference to the accompanying drawings, in which some,but not all embodiments of the invention are shown. Indeed, theinvention may be embodied in many different forms and should not beconstrued as limited to the embodiments set forth herein.

While the present invention is susceptible to various modifications andalternative forms, exemplary embodiments thereof are shown by way ofexample in the drawings and are herein described in detail. It should beunderstood, however, that the description of exemplary embodiments isnot intended to limit the invention to the particular forms disclosed,but on the contrary, the intention is to cover all modifications,equivalents and alternatives falling within the spirit and scope of theinvention as defined by the embodiments above and the claims below.Reference should therefore be made to the embodiments above and claimsbelow for interpreting the scope of the invention.

DETAILED DESCRIPTION

By way of introduction, the present disclosure describes the synthesisand characterization of biological activity of novel derivatives of aclass of biological lipid mediators known as endocannabinoids. In thisdisclosure, derivatives of endocannabinoids at both the epoxide and theamide ends improve the biological properties of the compositions byreducing hydrolytic susceptibility in the body and increasing thelongevity of the molecules. The synthesis of these derivatives is basedon rational design to reduce the hydrolytic susceptibility of thesegroups to sEH and FAAH. Furthermore, these derivatives retainanti-inflammatory, anti-cancer, anti-platelet aggregation andanti-angiogenic properties. By improving the biological stability, thesemolecules are better candidates for therapeutics.

1. DEFINITIONS

As described herein, compounds of the invention can optionally besubstituted with one or more substituents, such as are illustratedgenerally above, or as exemplified by particular classes, subclasses,and species of the invention. As described herein, the variables informula I encompass specific groups, such as, for example, alkyl andcycloalkyl. As one of ordinary skill in the art will recognize,combinations of substituents envisioned by this invention are thosecombinations that result in the formation of stable or chemicallyfeasible compounds. The term “stable,” as used herein, refers tocompounds that are not substantially altered when subjected toconditions to allow for their production, detection, and preferablytheir recovery, purification, and use for one or more of the purposesdisclosed herein. In some embodiments, a stable compound or chemicallyfeasible compound is one that is not substantially altered when kept ata temperature of 40° C. or less, in the absence of moisture or otherchemically reactive conditions, for at least a week.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art. All publications, patent applications, patents and otherreferences mentioned herein are incorporated by reference in theirentirety. The materials, methods, and examples disclosed herein areillustrative only and not intended to be limiting.

The terms “comprise(s),” “include(s),” “having,” “has,” “can,”“contain(s),” and variants thereof, as used herein, are intended to beopen-ended transitional phrases, terms, or words that do not precludethe possibility of additional acts or structures. The singular forms“a,” “an” and “the” include plural references unless the context clearlydictates otherwise. The present disclosure also contemplates otherembodiments “comprising,” “consisting of” and “consisting essentiallyof,” the embodiments or elements presented herein, whether explicitlyset forth or not.

The modifier “about” used in connection with a quantity is inclusive ofthe stated value and has the meaning dictated by the context (forexample, it includes at least the degree of error associated with themeasurement of the particular quantity). The modifier “about” shouldalso be considered as disclosing the range defined by the absolutevalues of the two endpoints. For example, the expression “from about 2to about 4” also discloses the range “from 2 to 4.” The term “about” mayrefer to plus or minus 10% of the indicated number. For example, “about10%” may indicate a range of 9% to 11%, and “about 1” may mean from0.9-1.1. Other meanings of “about” may be apparent from the context,such as rounding off, so, for example “about 1” may also mean from 0.5to 1.4.

Definitions of specific functional groups and chemical terms aredescribed in more detail below. For purposes of this disclosure, thechemical elements are identified in accordance with the Periodic Tableof the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., inside cover, and specific functional groups are generally definedas described therein. Additionally, general principles of organicchemistry, as well as specific functional moieties and reactivity, aredescribed in Organic Chemistry, Thomas Sorrell, University ScienceBooks, Sausalito, 1999; Smith and March March's Advanced OrganicChemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock,Comprehensive Organic Transformations, VCH Publishers, Inc., New York,1989; Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition,Cambridge University Press, Cambridge, 1987, the entire contents of eachof which are incorporated herein by reference.

The term “alkyl” as used herein, means a straight or branched chainsaturated hydrocarbon. Representative examples of alkyl include, but arenot limited to, methyl, ethyl, npropyl, isopropyl, n-butyl, sec-butyl,isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl,n-octyl, n-nonyl, and n-decyl.

The term “alkylene,” as used herein, means a divalent group derived froma straight or branched chain saturated hydrocarbon. Representativeexamples of alkylene include, but are not limited to, —CH₂—, —CH₂CH₂—,—CH₂CH₂CH₂—, —CH₂CH(CH₃)CH₂—, and CH₂CH(CH₃)CH(CH)CH₂—.

The term “aryl,” as used herein, means phenyl or a bicyclic aryl. Thebicyclic aryl is naphthyl, dihydronaphthalenyl, tetrahydronaphthalenyl,indanyl, or indenyl. The phenyl and bicyclic aryls are attached to theparent molecular moiety through any carbon atom contained within thephenyl or bicyclic aryl.

The term “cyano” as used herein, represents a group of formula —CN.

The term “cycloalkyl” as used herein, means a monovalent group derivedfrom an all-carbon non-aromatic ring system containing zero heteroatomsas ring atoms, and zero double bonds. The all-carbon ring system can bea monocyclic, bicylic, or tricyclic ring system, and can be a fused ringsystem, a bridged ring system, or a spiro ring system, or combinationsthereof. Examples of cycloalkyls include, but are not limited to,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclooctyl, and

The cycloalkyl groups described herein can be appended to the parentmolecular moiety through any substitutable carbon atom.

The term “cycloalkenyl” as used herein, means a monovalent group derivedfrom an all-carbon non-aromatic ring system containing zero heteroatomsas ring atoms, and at least one carbon-carbon double bond. Thecycloalkenyl may have from 5-10 carbon atoms as ring atoms. Thecycloalkenyl may be monocyclic, bicyclic, bridged, fused, orspirocyclic. Exemplary monocyclic cycloalkenyl rings includecyclopentenyl, cyclohexenyl, cycloheptenyl, and bicyclo[2.2.1]heptenyl.

The term “halogen” means a chlorine, bromine, iodine, or fluorine atom.

The term “haloalkyl,” as used herein, means an alkyl group, as definedherein, in which one, two, three, four, five, six, seven or eighthydrogen atoms are replaced by a halogen.

The term “heteroaryl,” as used herein, means an aromatic heterocycle,i.e., an aromatic ring that contains at least one heteroatom selectedfrom O, N, or S. A heteroaryl may contain from 5 to 12 ring atoms. Aheteroaryl may be a 5- to 6-membered monocyclic heteroaryl or an 8- to12-membered bicyclic heteroaryl. A 5-membered monocyclic heteroaryl ringcontains two double bonds, and one, two, three, or four heteroatoms asring atoms. Representative examples of 5-membered monocyclic heteroarylsinclude, but are not limited to, furanyl, imidazolyl, isoxazolyl,isothiazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyrrolyl, tetrazolyl,thiadiazolyl, thiazolyl, thienyl, and triazolyl. A 6-membered heteroarylring contains three double bonds, and one, two, three or fourheteroatoms as ring atoms. Representative examples of 6-memberedmonocyclic heteroaryls include, but are not limited to, pyridinyl,pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl. The bicyclicheteroaryl is an 8- to 12-membered ring system having a monocyclicheteroaryl fused to an aromatic, saturated, or partially saturatedcarbocyclic ring, or fused to a second monocyclic heteroaryl ring.Representative examples of bicyclic heteroaryl include, but are notlimited to, benzofuranyl, benzoxadiazolyl, 1,3-benzothiazolyl,benzimidazolyl, benzothienyl, indolyl, indazolyl, isoquinolinyl,naphthyridinyl, oxazolopyridine, quinolinyl, thienopyridinyl, 5, 6, 7,8-tetrahydroquinolinyl, and 6, 7-dihydro-5H-cyclopenta[b]pyridinyl. Theheteroaryl groups are connected to the parent molecular moiety throughany substitutable carbon atom or any substitutable nitrogen atomcontained within the groups.

The terms “heterocycle” or “heterocyclic” refer generally to ringsystems containing at least one heteroatom as a ring atom where theheteroatom is selected from oxygen, nitrogen, and sulfur. In someembodiments, a nitrogen or sulfur atom of the heterocycle is optionallysubstituted with oxo. Heterocycles may be a monocyclic heterocycle, afused bicyclic heterocycle, or a spiro heterocycle. The monocyclicheterocycle is generally a 4, 5, 6, 7, or 8-membered non-aromatic ringcontaining at least one heteroatom selected from O, N, or S. The4-membered ring contains one heteroatom and optionally one double bond.The 5-membered ring contains zero or one double bond and one, two orthree heteroatoms. The 6, 7, or 8-membered ring contains zero, one, ortwo double bonds, and one, two, or three heteroatoms. Representativeexamples of monocyclic heterocycle include, but are not limited to,azetidinyl, azepanyl, diazepanyl, 1,3-dioxanyl, 1,4-dioxanyl,1,3-dioxolanyl, 4,5-dihydroisoxazol-5-yl, 3,4-dihydropyranyl,1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl,isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl,morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl,oxetanyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl,pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl,tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl,thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl, thiopyranyl,and trithianyl. The fused bicyclic heterocycle is a 7-12-membered ringsystem having a monocyclic heterocycle fused to a phenyl, to a saturatedor partially saturated carbocyclic ring, or to another monocyclicheterocyclic ring, or to a monocyclic heteroaryl ring. Representativeexamples of fused bicyclic heterocycle include, but are not limited to,1,3-benzodioxol-4-yl, 1,3-benzodithiolyl, 3-azabicyclo[3.1.0]hexanyl,hexahydro-1H-furo[3,4-c]pyrrolyl, 2,3-dihydro-1,4-benzodioxinyl,2,3-dihydro-1-benzofuranyl, 2,3-dihydro-1-benzothienyl,2,3-dihydro-1H-indolyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, and1,2,3,4-tetrahydroquinolinyl. Spiro heterocycle means a 4-, 5-, 6-, 7-,or 8-membered monocyclic heterocycle ring wherein two of thesubstituents on the same carbon atom form a second ring having 3, 4, 5,6, 7, or 8 members. Examples of a spiro heterocycle include, but are notlimited to, 1,4-dioxa-8-azaspiro[4.5]decanyl,2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.3]heptanyl, and8-azaspiro[4.5]decane. The monocyclic heterocycle groups of the presentinvention may contain an alkylene bridge of 1, 2, or 3 carbon atoms,linking two nonadjacent atoms of the group. Examples of such a bridgedheterocycle include, but are not limited to,2,5-diazabicyclo[2.2.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl,2-azabicyclo[2.2.2]octanyl, and oxabicyclo[2.2.1]heptanyl. Themonocyclic, fused bicyclic, and spiro heterocycle groups are connectedto the parent molecular moiety through any substitutable carbon atom orany substitutable nitrogen atom contained within the group.

The term “hydroxy” as used herein, means an —OH group.

Terms such as “alkyl,” “cycloalkyl,” “alkylene,” etc. as used herein maybe preceded by a designation indicating the number of atoms present inthe group in a particular instance (e.g., “C₁₋₄alkyl,” “C₃₋₆cycloalkyl,”“C₁₋₄alkylene”). These designations are used as generally understood bythose skilled in the art. For example, the representation “C” followedby a subscripted number indicates the number of carbon atoms present inthe group that follows. Thus, “C₃alkyl” is an alkyl group with threecarbon atoms (i.e., n-propyl, isopropyl). Where a range is given, as in“C₁₋₄,” the members of the group that follows may have any number ofcarbon atoms falling within the recited range. A “C₁₋₄alkyl,” forexample, is an alkyl group having from 1 to 4 carbon atoms, howeverarranged (i.e., straight chain or branched).

If a group is described as being “substituted”, a non-hydrogensubstituent group is in the place of hydrogen radical on a carbon ornitrogen of that group. Thus, for example, a substituted alkyl is analkyl in which at least one non-hydrogen radical is in the place of ahydrogen radical on the alkyl. To illustrate, monofluoroalkyl is alkylsubstituted with a fluoro radical, and difluoroalkyl is alkylsubstituted with two fluoro radicals. It should be recognized that ifthere is more than one substitution on a substituent, each non-hydrogenradical may be identical or different (unless otherwise stated).Substituent groups include, but are not limited to, halogen, ═O, ═S,cyano, nitro, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkyl,alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl,cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl,heteroarylalkyl, arylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl,alkylene, aryloxy, phenoxy, benzyloxy, amino, alkylamino, acylamino,aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl,alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, —COOH, ketone,amide, carbamate, and acyl.

When a group is referred to as “unsubstituted” or not referred to as“substituted” or “optionally substituted”, it means that the group doesnot have any substituents. If a group is described as being “optionallysubstituted”, the group may be either (1) not substituted or (2)substituted. If a group is described as being optionally substitutedwith up to a particular number of non-hydrogen radicals, that group maybe either (1) not substituted; or (2) substituted by up to thatparticular number of substituent groups or by up to the maximum numberof substitutable positions on that group, whichever is less.

If substituents are described as being independently selected from agroup, each substituent is selected independent of the other. Eachsubstituent, therefore, may be identical to or different from the othersubstituent(s).

Unless otherwise stated, structures depicted herein are also meant toinclude all isomeric (e.g., enantiomeric, diastereomeric, and geometric(or conformational)) forms of the structure; for example, the R and Sconfigurations for each asymmetric center, (Z) and (E) double bondisomers, and (Z) and (E) conformational isomers. Therefore, singlestereochemical isomers as well as enantiomeric, diastereomeric, andgeometric (or conformational) mixtures of the present compounds arewithin the scope of the invention. Unless otherwise stated, alltautomeric forms of the compounds of the invention are within the scopeof the invention. Thus, included within the scope of the invention aretautomers of compounds of formula I. The structures also includezwitterioinc forms of the compounds or salts of formula I whereappropriate.

The terms “effective amount” or “therapeutically effective amount,” asused herein, refer to a sufficient amount of an agent or a compositionor combination of compositions being administered which will relieve tosome extent one or more of the symptoms of the disease or conditionbeing treated. The result can be reduction and/or alleviation of thesigns, symptoms, or causes of a disease, or any other desired alterationof a biological system. For example, an “effective amount” fortherapeutic uses is the amount of the composition comprising a compoundas disclosed herein required to provide a clinically significantdecrease in disease symptoms. An appropriate “effective” amount in anyindividual case may be determined using techniques, such as a doseescalation study. The dose could be administered in one or moreadministrations. However, the precise determination of what would beconsidered an effective dose may be based on factors individual to eachpatient, including, but not limited to, the patient's age, size, type orextent of disease, stage of the disease, route of administration of theregenerative cells, the type or extent of supplemental therapy used,ongoing disease process and type of treatment desired (e.g., aggressivevs. conventional treatment).

As used herein, “treat,” “treating” and the like means a slowing,stopping or reversing of progression of cancer when provided acomposition described herein to an appropriate control subject. The termalso means a reversing of the progression of such a disease or disorderto a point of eliminating or greatly reducing the cell proliferation. Assuch, “treating” means an application or administration of thecompositions described herein to a subject, where the subject has adisease or a symptom of a disease, where the purpose is to cure, heal,alleviate, relieve, alter, remedy, ameliorate, improve or affect thedisease or symptoms of the disease.

As used herein, “subject” or “patient” means an individual havingsymptoms of, or at risk for, cancer, increased inflammation, increasedplatelet aggregation, increased angiogenesis, or other disease ordisorder. A patient may be human or non-human and may include, forexample, animal strains or species used as “model systems” for researchpurposes, such a mouse model as described herein. Likewise, patient mayinclude either adults or juveniles (e.g., children). Moreover, patientmay mean any living organism, preferably a mammal (e.g., human ornon-human) that may benefit from the administration of compositionscontemplated herein. Examples of mammals include, but are not limitedto, any member of the Mammalian class: humans, non-human primates suchas chimpanzees, and other apes and monkey species; farm animals such ascattle, horses, sheep, goats, swine; domestic animals such as rabbits,dogs, and cats; laboratory animals including rodents, such as rats, miceand guinea pigs, and the like. Examples of non-mammals include, but arenot limited to, birds, fish and the like. In one embodiment of themethods and compositions provided herein, the mammal is a human.

As used herein, the terms “providing”, “administering,” “introducing,”are used interchangeably herein and refer to the placement of thecompositions of the disclosure into a subject by a method or route whichresults in at least partial localization of the composition to a desiredsite. The compositions can be administered by any appropriate routewhich results in delivery to a desired location in the subject.

2. COMPOUNDS

In one aspect, the present disclosure provides compounds or compositionsof formula (I), or a pharmaceutically acceptable salt thereof,

wherein,

one of L¹, L², L³, L⁴, L⁵, and L⁶ is

and the others of L¹, L², L³, L⁴, L⁵, and L⁶ are

is 3- to 6-membered ring containing at least one heteroatom selectedfrom the group consisting of oxygen, nitrogen, and sulfur;

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x1), -G¹, or—C₁₋₆alkylene-G¹;

G¹ is C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl, heteroaryl, orheterocycle, wherein G¹ is optionally substituted with 1, 2, 3, or 4R^(x1);

R² is C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x2), -G², or—C₁₋₆alkylene-G²;

G² is C₃₋₈-cycloalkyl, C₃₋₈cycloalkenyl, aryl, heteroaryl, orheterocycle, wherein G² is optionally substituted with 1, 2, 3, or 4R^(x2);

R^(x1) and R^(x2) at each occurrence are independently cyano, —OH,—OC₁₋₄alkyl, —OC(O)C₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl),—NHC(O)C₁₋₄alkyl, or —N(C₁₋₄alkyl)C(O)C₁₋₄alkyl;

provided that R² is not —CH₂CH₂OH when

In some embodiments, L¹ is

and L², L³, L⁴, L⁵, and L⁶ are

i.e., compounds of formula (I) have formula (I-a).

In some embodiments, compounds of formula (I-a) have formula (I-aa),wherein X is O, NH, or S.

In some embodiments, L² is

and L¹, L³, L⁴, L⁵, and L⁶ are

i.e., compounds of formula (I) have formula (I-b).

In some embodiments, compounds of formula (I-b) have formula (I-ba),wherein X is O, NH, or S.

In some embodiments, L¹ is

and L¹, L², L⁴, L⁵, and L⁶ are

i.e., compounds of formula (I) have formula (I-c).

In some embodiments, compounds of formula (I-c) have formula (I-ca),wherein X is O, NH, or S.

In some embodiments, L⁴ is

and L¹, L², L³, L⁵, and L⁶ are

i.e., compounds of formula (I) have formula (I-d).

In some embodiments, compounds of formula (I-d) have formula (I-da),wherein X is O, NH, or S.

In some embodiments, L⁵ is

and L¹, L², L³, L⁴, and L⁶ are

i.e., compounds of formula (I) have formula (I-e).

In some embodiments, compounds of formula (I-e) have formula (I-ea),wherein X is O, NH, or S.

In some embodiments, L⁶ is

and L¹, L², L³, L⁴, and L⁵ are

i.e., compounds of formula (I) have formula (I-f).

In some embodiments, compounds of formula (I-f) have formula (I-fa),wherein X is O, NH, or S.

In some embodiments,

In some embodiments, R¹ is hydrogen, C₁₋₆alkyl (such as methyl orethyl), or C₁₋₆haloalkyl (such as chloromethyl or chloroethyl). In someembodiments, R¹ is hydrogen. In some embodiments

and R¹ is hydrogen.

In some embodiments, R² is C₁₋₆alkyl, —C₁₋₆alkylene-R^(x2), -G², or—C₁₋₆alkylene-G². For example, R² may be C₁₋₆alkyl, such as n-butyl,sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, orn-hexyl. For example, R² may be —C₁₋₆alkylene-R^(x2), such as—CH₂CH₂—R^(x2), —CH₂CH₂CH₂—R^(x2), or —CH(CH)CH₂—R^(x2). For example, R²may be -G² or —C₁₋₆alkylene-G², and G² is C₃₋₈cycloalkyl,C₃₋₈cycloalkenyl, aryl, heteroaryl, or heterocycle, wherein G² isoptionally substituted with 1, 2, 3, or 4 R^(x2).

In some embodiments, G¹ or G² is a C₃₋₈cycloalkyl optionally substitutedwith 1, 2, 3, or 4 R^(x2). For example, G¹ or G² may be

which is optionally substituted with 1, 2, or 3 R^(x2). In someembodiments, R² is -G or —C₁₋₆alkylene-G², and G² is a C₃₋₈cycloalkyloptionally substituted with 1, 2, 3, or 4 R^(x2). In some embodiments,R² is -G² or —C₁₋₆alkylene-G², and G² is

which is optionally substituted with 1, 2, or 3 R^(x2).

In some embodiments, R^(x1) and R^(x2) at each occurrence areindependently —OH, —OC₁₋₄alkyl, —OC(O)C₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl, or—N(C₁₋₄alkyl)₂. In some embodiments, R^(x2) at each occurrence isindependently —OH or —NH₂. For example, R² may be —C₁₋₆alkylene-OH (suchas —CH₂CH₂CH₂—OH, or —CH(CH₃)CH₂—OH) or —C₁₋₆alkylene-NH₂. For example,R² may be -G² or —C₁₋₆alkylene-G², wherein G² is a C₃-cycloalkyl,C₃₋₈cycloalkenyl, aryl, heteroaryl, or heterocycle as defined herein,wherein G² is optionally substituted with 1, 2, 3, or 4 R^(x2), andwherein R^(x2) at each occurrence is independently —OH or —NH₂. In someembodiments, R² is

In some embodiments

R¹ is hydrogen, and R² is C₁₋₆alkyl.

In some embodiments,

R¹ is hydrogen, and R² is C₁₋₆alkylene-R^(x2) as described herein. Insome embodiments,

R¹ is hydrogen, and R² is —C₁₋₆alkylene-OH (such as

or —C₁₋₆alkylene-NH₂.

In some embodiments,

R¹ is hydrogen, R² is —C₁₋₆alkylene-OH. In some embodiments,

R¹ is hydrogen, R² is —C₁₋₆alkylene-NH₂. In some embodiments,

R¹ is hydrogen, R² is —C₁₋₆alkylene-OH. In some embodiments,

R¹ is hydrogen, R² is —C₁₋₆alkylene-NH₂. In some embodiments,

R¹ is hydrogen, R² is —C₁₋₆alkylene-OH. In some embodiments,

R¹ is hydrogen, R² is —C₁₋₆alkylene-NH₂.

In some embodiments,

R¹ is hydrogen, and R² is -G² or —C₁₋₆alkylene-G², in which G² andR^(x2) are as described herein. In some embodiments,

R¹ is hydrogen, R² is -G² or —C₁₋₆alkylene-G², and G² is aC₃₋₈cycloalkyl optionally substituted with 1, 2, 3, or 4 R^(x2). In someembodiments,

R¹ is hydrogen, R² is -G² or —C₁₋₆alkylene-G², G² is a C₃₋₈cycloalkyloptionally substituted with 1, 2, 3, or 4 R^(x2), and R^(x2) at eachoccurrence is independently —OH or —NH₂.

In some embodiments,

R¹ is hydrogen, R² is -G² or —C₁₋₆alkylene-G², and G² is

wherein G² is unsubstituted or substituted with 1 or 2 R^(x2), R^(x2) ateach occurrence being independently —OH or —NH₂.

In some embodiments,

R¹ is hydrogen, R² is

In some embodiments,

R¹ is hydrogen, R² is

In some embodiments,

R¹ is hydrogen, R² is

In some embodiments, the compound of formula (I) is selected from thegroup consisting of

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of formula (I) is a compound shown inFIGS. 1B, 1C, and/or 1D.

Also provided herein is a compound or composition comprising thestructure (i):

wherein,

R₁ and R₂ is selected from carbon chain with an n=3, 4, 5 or 6 ending inCH₃, —OH, or —NH₂, saturated cyclic rings with 3, 4, 5 or 6 carbons withno substitutions, saturated cyclic rings with 3, 4, 5 or 6 carbons withsubstitutions of —OH and —NH₂, unsaturated cyclic rings with 3, 4, 5 or6 carbons with no substitutions, unsaturated cyclic rings with 3, 4, 5or 6 carbons with substitutions of —OH and —NH₂, aromatic groups with nosubstitutions, aromatic groups with substitutions of —OH or —NH₂, andsaturated or unsaturated cyclic rings containing N, O or S, and

R₃ is selected from 3, 4, 5 or 6 membered rings containing oxygen,nitrogen or sulfur.

In some embodiments, the compound or composition is selected from thegroup consisting of

A compound described herein can be in the form of a salt, e.g., apharmaceutically acceptable salt. As used herein, the term“pharmaceutically acceptable salt” refers to those salts which are,within the scope of sound medical judgement, suitable for use in contactwith the tissues of humans and lower animals without undue toxicity,irritation, allergic response and the like, and are commensurate with areasonable benefit/risk ratio. Pharmaceutically acceptable salts arewell known in the art. For example, S. M. Berge, et al. describepharmaceutically acceptable salts in detail in J PharmaceuticalSciences, 1977, 66, 1-19, incorporated herein by reference.Pharmaceutically acceptable salts of the compounds of this inventioninclude those derived from suitable inorganic and organic acids andbases. Examples of pharmaceutically acceptable, nontoxic acid additionsalts are salts of an amino group formed with inorganic acids such ashydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid andperchloric acid or with organic acids such as acetic acid, oxalic acid,maleic acid, tartaric acid, citric acid, succinic acid or malonic acidor by using other methods used in the art such as ion exchange. Otherpharmaceutically acceptable salts include adipate, alginate, ascorbate,aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate,camphorate, camphorsulfonate, citrate, cyclopentanepropionate,digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate,glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate,hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate,oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate,phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate,tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts,and the like. Salts derived from appropriate bases include alkali metal,alkaline earth metal, ammonium and N(C₁₋₄alkyl)₄ salts. This inventionalso envisions the quaternization of any basic nitrogen-containinggroups of the compounds disclosed herein. Water or oil-soluble ordispersable products may be obtained by such quaternization.Representative alkali or alkaline earth metal salts include sodium,lithium, potassium, calcium, magnesium, and the like. Furtherpharmaceutically acceptable salts include, when appropriate, nontoxicammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate,nitrate, lower alkyl sulfonate and aryl (e.g., phenyl/substitutedphenyl) sulfonate.

The compounds or compositions disclosed herein may includeisotope-labelled forms. An isotope-labelled form of a compound isidentical to the compound apart from the fact that one or more atoms ofthe compound have been replaced by an atom or atoms having an atomicmass or mass number which differs from the atomic mass or mass number ofthe atom which usually occurs in greater natural abundance. Examples ofisotopes which are readily commercially available and which can beincorporated into a compound by well-known methods include isotopes ofhydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, for example2H, 3H, 13C, 14C, 15N, 18O, 17O, 18F and 36Cl.

3. PHARMACEUTICAL COMPOSITIONS

In another aspect, the present disclosure provides a pharmaceuticalcomposition are provided, which comprises a compound as described hereinor a pharmaceutically acceptable salt thereof, and optionally apharmaceutically acceptable carrier, adjuvant or vehicle. In certainembodiments, these pharmaceutical compositions optionally furthercomprise one or more additional therapeutic agents. In one embodiment,the pharmaceutical composition comprises a therapeutically effectiveamount of a compound as described herein, or a pharmaceuticallyacceptable salt thereof, and one or more pharmaceutically acceptablecarriers or vehicles.

Pharmaceutical compositions of the present invention may be manufacturedby processes well known in the art, e.g., by means of conventionalmixing, dissolving, granulating, dragee-making, levigating, emulsifying,encapsulating, entrapping or lyophilizing processes.

As used herein, the term “pharmaceutically acceptable salt” refers tothose salts which are, within the scope of sound medical judgement,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response and the like, andare commensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, S. M Berge, etal. describe pharmaceutically acceptable salts in detail in JPharmaceutical Sciences, 1977, 66, 1-19, incorporated herein byreference. Pharmaceutically acceptable salts of the compounds of thisinvention include those derived from suitable inorganic and organicacids and bases. Examples of pharmaceutically acceptable, nontoxic acidaddition salts are salts of an amino group formed with inorganic acidssuch as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuricacid and perchloric acid or with organic acids such as acetic acid,oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid ormalonic acid or by using other methods used in the art such as ionexchange. Other pharmaceutically acceptable salts include adipate,alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike. Salts derived from appropriate bases include alkali metal,alkaline earth metal, ammonium and N(C1-4alkyl)4 salts. This inventionalso envisions the quaternization of any basic nitrogen-containinggroups of the compounds disclosed herein. Water or oil-soluble ordispersable products may be obtained by such quaternization.Representative alkali or alkaline earth metal salts include sodium,lithium, potassium, calcium, magnesium, and the like. Furtherpharmaceutically acceptable salts include, when appropriate, nontoxicammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate,nitrate, lower alkyl sulfonate and aryl (e.g., phenyl/substitutedphenyl) sulfonate.

As described herein, the pharmaceutically acceptable compositions of theinvention additionally comprise a pharmaceutically acceptable carrier,adjuvant, or vehicle, which, as used herein, includes any and allsolvents, diluents, or other liquid vehicle, dispersion or suspensionaids, surface active agents, isotonic agents, thickening or emulsifyingagents, preservatives, solid binders, lubricants and the like, as suitedto the particular dosage form desired. Remington's PharmaceuticalSciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton,Pa., 1980) discloses various carriers used in formulatingpharmaceutically acceptable compositions and known techniques for thepreparation thereof. Except insofar as any conventional carrier mediumis incompatible with the compounds of the invention, such as byproducing any undesirable biological effect or otherwise interacting ina deleterious manner with any other component(s) of the pharmaceuticallyacceptable composition, its use is contemplated to be within the scopeof this invention. Some examples of materials which can serve aspharmaceutically acceptable carriers include, but are not limited to,ion exchangers, alumina, aluminum stearate, lecithin, serum proteins,such as human serum albumin, buffer substances such as phosphates,glycine, sorbic acid, or potassium sorbate, partial glyceride mixturesof saturated vegetable fatty acids, water, salts or electrolytes, suchas protamine sulfate, disodium hydrogen phosphate, potassium hydrogenphosphate, sodium chloride, zinc salts, colloidal silica, magnesiumtrisilicate, polyvinyl pyrrolidone, polyacrylates, waxes,polyethylenepolyoxypropylene-block polymers, wool fat, sugars such aslactose, glucose and sucrose; starches such as com starch and potatostarch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth;malt; gelatin; talc; excipients such as cocoa butter and suppositorywaxes; oils such as peanut oil, cottonseed oil; safflower oil; sesameoil; olive oil; com oil and soybean oil; glycols; such a propyleneglycol or polyethylene glycol; esters such as ethyl oleate and ethyllaurate; agar; buffering agents such as magnesium hydroxide and aluminumhydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'ssolution; ethyl alcohol, and phosphate buffer solutions, as well asother non-toxic compatible lubricants such as sodium lauryl sulfate andmagnesium stearate, as well as coloring agents, releasing agents,coating agents, sweetening, flavoring and perfuming agents,preservatives and antioxidants can also be present in the composition,according to the judgment of the formulator.

The pharmaceutically acceptable compositions of this invention can beadministered to humans and other animals orally, rectally, parenterally,intracistemally, intravaginally, intraperitoneally, topically (as bypowders, ointments, or drops), bucally, as an oral or nasal spray, orthe like, depending on the severity of the disease being treated.

Pharmaceutical compositions for parenteral injection comprisepharmaceutically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions or emulsions as well as sterile powders forreconstitution into sterile injectable solutions or dispersions justprior to use. Examples of suitable aqueous and nonaqueous carriers,diluents, solvents or vehicles include water, ethanol, polyols (such asglycerol, propylene glycol, polyethylene glycol and the like), vegetableoils (such as olive oil), injectable organic esters (such as ethyloleate) and suitable mixtures thereof. Proper fluidity can bemaintained, for example, by the use of coating materials such aslecithin, by the maintenance of the required particle size in the caseof dispersions and by the use of surfactants.

These compositions can also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofthe action of microorganisms can be ensured by the inclusion of variousantibacterial and antifungal agents, for example, paraben,chlorobutanol, phenol sorbic acid and the like. It can also be desirableto include isotonic agents such as sugars, sodium chloride and the like.Prolonged absorption of the injectable pharmaceutical form can bebrought about by the inclusion of agents which delay absorption such asaluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it isdesirable to slow the absorption of the drug from subcutaneous orintramuscular injection. This can be accomplished by the use of a liquidsuspension of crystalline or amorphous material with poor watersolubility. The rate of absorption of the drug then depends upon itsrate of dissolution which, in turn, can depend upon crystal size andcrystalline form. Alternatively, delayed absorption of a parenterallyadministered drug form is accomplished by dissolving or suspending thedrug in an oil vehicle.

Liquid dosage forms for oral administration include, but are not limitedto, pharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups and elixirs. In addition to the active compounds,the liquid dosage forms may contain inert diluents commonly used in theart such as, for example, water or other solvents, solubilizing agentsand emulsifiers such as ethyl alcohol, isopropyl alcohol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butylene glycol, dimethylformamide, oils (in particular,cottonseed, groundnut, corn, germ, olive, castor, and sesame oils),glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fattyacid esters of sorbitan, and mixtures thereof. Besides inert diluents,the oral compositions can also include adjuvants such as wetting agents,emulsifying and suspending agents, sweetening, flavoring, and perfumingagents.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, cement, putty, and granules. In such solid dosage forms,the active compound can be mixed with at least one inert,pharmaceutically acceptable excipient or carrier, such as sodium citrateor dicalcium phosphate and/or a) fillers or extenders such as starches,lactose, sucrose, glucose, mannitol and silicic acid; b) binders such ascarboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone,sucrose and acacia; c) humectants such as glycerol; d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates and sodium carbonate; e) solutionretarding agents such as paraffin; f) absorption accelerators such asquaternary ammonium compounds; g) wetting agents such as cetyl alcoholand glycerol monostearate; h) absorbents such as kaolin and bentoniteclay and i) lubricants such as talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate and mixturesthereof. In the case of capsules, tablets and pills, the dosage form canalso comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hardfilled gelatin capsules using such excipients as lactose ormilk sugar as well as high molecular weight polyethylene glycols and thelike. The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They may optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions that can be usedinclude polymeric substances and waxes. Solid compositions of a similartype may also be employed as fillers in soft and hard-filled gelatincapsules using such excipients as lactose or milk sugar as well as highmolecular weight polyethylene glycols and the like.

The active compounds can also be in microencapsulated form with one ormore excipients as noted above. The solid dosage forms of tablets,dragees, capsules, pills, and granules can be prepared with coatings andshells such as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active compound may be admixed with at least one inertdiluent such as sucrose, lactose or starch. Such dosage forms may alsocomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets and pills, the dosage forms may also comprisebuffering agents. They may optionally contain opacifying agents and canalso be of a composition that they release the active ingredient(s)only, or preferentially, in a certain part of the intestinal tract,optionally, in a delayed manner. Examples of embedding compositions thatcan be used include polymeric substances and waxes.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating excipients or carriers such ascocoa butter, polyethylene glycol or a suppository wax which are solidat ambient temperature but liquid at body temperature and therefore meltin the rectum or vaginal cavity and release the active compound.

Dosage forms for topical or trans dermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. The active componentis admixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives or buffers as may be required.Ophthalmic formulation, eardrops, and eye drops are also contemplated asbeing within the scope of this invention. Additionally, the inventioncontemplates the use of transdermal patches, which have the addedadvantage of providing controlled delivery of a compound to the body.Such dosage forms are prepared by dissolving or dispensing the compoundin the proper medium. Absorption enhancers can also be used to increasethe flux of the compound across the skin. The rate can be controlled byeither providing a rate controlling membrane or by dispersing thecompound in a polymer matrix or gel.

Compounds described herein can be administered as a pharmaceuticalcomposition comprising the compounds of interest in combination with oneor more pharmaceutically acceptable carriers. The phrase“therapeutically effective amount” of the present compounds meanssufficient amounts of the compounds to treat disorders, at a reasonablebenefit/risk ratio applicable to any medical treatment. It isunderstood, however, that the total daily dosage of the compounds andcompositions can be decided by the attending physician within the scopeof sound medical judgment. The specific therapeutically effective doselevel for any particular patient can depend upon a variety of factorsincluding the disorder being treated and the severity of the disorder;activity of the specific compound employed; the specific compositionemployed; the age, body weight, general health and prior medicalhistory, sex and diet of the patient; the time of administration, routeof administration, and rate of excretion of the specific compoundemployed; the duration of the treatment; drugs used in combination orcoincidental with the specific compound employed; and like factorswell-known in the medical arts. For example, it is well within the skillof the art to start doses of the compound at levels lower than requiredto achieve the desired therapeutic effect and to gradually increase thedosage until the desired effect is achieved. Actual dosage levels ofactive ingredients in the pharmaceutical compositions can be varied soas to obtain an amount of the active compound(s) that is effective toachieve the desired therapeutic response for a particular patient and aparticular mode of administration. In the treatment of certain medicalconditions, repeated or chronic administration of compounds can berequired to achieve the desired therapeutic response. “Repeated orchronic administration” refers to the administration of compounds daily(i.e., every day) or intermittently (i.e., not every day) over a periodof days, weeks, months, or longer.

The compositions described herein may be administered with additionalcompositions to prolong stability, delivery, and/or activity of thecompositions, or combined with additional therapeutic agents, orprovided before or after the administration of additional therapeuticagents.

Combination therapy includes administration of a single pharmaceuticaldosage formulation containing one or more of the compounds describedherein and one or more additional pharmaceutical agents, as well asadministration of the compounds and each additional pharmaceuticalagent, in its own separate pharmaceutical dosage formulation. Forexample, a compound described herein and one or more additionalpharmaceutical agents, can be administered to the patient together, in asingle oral dosage composition having a fixed ratio of each activeingredient, such as a tablet or capsule; or each agent can beadministered in separate oral dosage formulations. Where separate dosageformulations are used, the present compounds and one or more additionalpharmaceutical agents can be administered at essentially the same time(e.g., concurrently) or at separately staggered times (e.g.,sequentially).

It will be appreciated that appropriate dosages of the compounds, andcompositions comprising the compounds, can vary from patient to patient.Determining the optimal dosage will generally involve the balancing ofthe level of therapeutic benefit against any risk or deleterious sideeffects of the treatments of the present invention. The selected dosagelevel will depend on a variety of factors including, but not limited to,the activity of the particular compound, the route of administration,the time of administration, the rate of excretion of the compound, theduration of the treatment, other drugs, compounds, and/or materials usedin combination, and the age, sex, weight, condition, general health, andprior medical history of the patient. The amount of compound and routeof administration will ultimately be at the discretion of the physician,although generally the dosage will be to achieve local concentrations atthe site of action which achieve the desired effect without causingsubstantial harmful or deleterious side-effects.

For example, a therapeutically effective amount of a compound of formula(I), may be about 1 mg/kg to about 1000 mg/kg, about 5 mg/kg to about950 mg/kg, about 10 mg/kg to about 900 mg/kg, about 15 mg/kg to about850 mg/kg, about 20 mg/kg to about 800 mg/kg, about 25 mg/kg to about750 mg/kg, about 30 mg/kg to about 700 mg/kg, about 35 mg/kg to about650 mg/kg, about 40 mg/kg to about 600 mg/kg, about 45 mg/kg to about550 mg/kg, about 50 mg/kg to about 500 mg/kg, about 55 mg/kg to about450 mg/kg, about 60 mg/kg to about 400 mg/kg, about 65 mg/kg to about350 mg/kg, about 70 mg/kg to about 300 mg/kg, about 75 mg/kg to about250 mg/kg, about 80 mg/kg to about 200 mg/kg, about 85 mg/kg to about150 mg/kg, and about 90 mg/kg to about 100 mg/kg.

It will be readily apparent to those skilled in the art that othersuitable modifications and adaptations of the compounds and methods ofthe present disclosure described herein are readily applicable andappreciable, and may be made using suitable equivalents withoutdeparting from the scope of the present disclosure or the aspects andembodiments disclosed herein. Having now described the presentdisclosure in detail, the same will be more clearly understood byreference to the following examples which are merely intended only toillustrate some aspects and embodiments of the disclosure, and shouldnot be viewed as limiting to the scope of the disclosure. Thedisclosures of all journal references, U.S. patents and publicationsreferred to herein are hereby incorporated by reference in theirentireties.

4. METHODS OF USE

The endocannabinoid system is involved in a broad range of functions andis implicated in a variety of physiological and pathological conditions(inflammation, immunomodulation, analgesia, cancer and others) asdescribed in Bifulco et al. (2007) Oncol Rep 17:813-816. The compoundsor compositions as disclosed herein, or pharmaceutically acceptablesalts thereof, or pharmaceutical compositions as described herein, maybe used for treating a disease, condition, or disorder in a subject. Forexample, the compounds or compositions disclosed herein may be used fortreating cancer, reducing inflammation, reducing platelet aggregation,reducing angiogenesis, or inducing vasoconstriction or vasodilation.

Cancer

Provided are uses of the compounds or compositions for treating cancer.Also provided are uses of the compounds or compositions in themanufacture of a medicament for treating cancer. The disclosed compoundsand compositions may be used in methods of treating cancer, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of a compound of formula (I), or a pharmaceutically acceptablesalt or pharmaceutical composition thereof.

Cancer is a class of diseases which occurs because cells becomeimmortalized; they fail to heed customary signals to turn off growthwhich is a normal function of remodeling in the body that requires cellsto die on cue. Apoptosis, or programmed cell death, can become defectiveand when this happens malignant transformation can take place. Theimmortalized cells grow beyond their normal limits and invade adjacenttissues. The malignant cells may also metastasize and spread to otherlocations in the body via the bloodstream or lymphatic system. Cancercells often form a mass known as a tumor.

Compounds of the present invention have functionalities that may beadvantageous for cancer treatment including inhibition of cellproliferation and induction of apoptosis. As a class of molecules,endocannabinoids and cannabinoids show anti-tumor effects in varioustumor cells, such as, e.g. neuroblastoma, mantle cell lymphoma, coloncancer, osteosarcoma, and glioma. Activation of the two cannabinoidreceptors, CB1 and CB2, can lead to the inhibition of cell proliferationand induction of apoptosis in multiple types of cancer cell linesresulting in the reduction of tumor growth in vivo.

The methods can be used with any cancer cell or in a subject having anytype of cancer, for example those described by the National CancerInstitute. The cancer may be a carcinoma, sarcoma, lymphoma, leukemia,melanoma, mesothelioma, multiple myeloma, or seminoma. In someembodiments, the cancer is an osteosarcoma. The cancer may be a cancerof the bladder, blood, bone, brain, breast, cervix, colon/rectum,endometrium, head and neck, kidney, liver, lung, muscle tissue, ovary,pancreas, prostate, skin, spleen, stomach, testicle, thyroid or uterus.

There are many different treatment options for cancer and the treatmentsought is often determined by the type and stage of the cancer.Treatment options include; chemotherapeutic drug treatment, hormonaldrug treatment, radiotherapy, surgery, complementary therapies andcombinations thereof. The compounds and compositions of the presentinvention may be used in combination with any well-known cancertreatment options.

Reducing Inflammation

By virtue of the anti-inflammatory properties shown herein, thecompounds and compositions according to the present invention may beuseful in a wide variety of indications having an inflammatory orautoimmune mechanism involved in their etiology or pathogenesis.Manipulation and use of endocannabinoids in vivo has been shown to be apotent treatment against inflammatory disorders.

Provided herein are uses of the compounds or compositions for reducinginflammation in a subject. Also provided herein are uses of thecompounds or compositions in the manufacture of a medicament forreducing inflammation in a subject. The disclosed compounds andcompositions may be used in various methods including methods ofreducing inflammation, comprising administering to a subject in needthereof a therapeutically effective amount of a compound of formula (I),or a pharmaceutically acceptable salt or pharmaceutical compositionthereof.

Inflammatory disorders underlie a vast variety of human diseases. Theimmune system is often involved with inflammatory disorders,demonstrated in both allergic reactions and some myopathies, with manyimmune system disorders resulting in abnormal inflammation. Compounds ofthe present invention may be used to reduce inflammation in a subjectsuffering from many acute and chronic diseases/disorders that areinflammatory in their nature including but not limited to rheumatoiddiseases e.g. rheumatoid arthritis, osteoarthritis, diseases of thevisceral system e.g. inflammatory bowel syndrome, ulcerative colitis,and Crohn's Disease, autoimmune diseases, e.g. lupus erythematodes, lungdiseases like asthma and COPD, Alzheimer's disease, cancer, multiplesclerosis, Psoriasis, sarcoidosis, and spondyloarthropathy (erg.ankylosing spondylitis).

Reduction in Platelet Aggregation

Provided herein are uses of the compounds or compositions for reducingplatelet aggregation in a subject. Also provided herein are uses of thecompounds or compositions in the manufacture of a medicament forreducing platelet aggregation in a subject. The disclosed compounds andcompositions may be used in various methods including methods ofreducing platelet aggregation, comprising administering to a subject inneed thereof a therapeutically effective amount of a compound of formula(I), or a pharmaceutically acceptable salt or pharmaceutical compositionthereof.

Platelets are small disc-shaped blood cells and their chief function isto maintain the integrity of the vascular system; not only duringinjury, but also day-to-day wear and tear. To do this, platelets can,when they come into contact with certain materials and chemicals undergoa process known as the aggregation-adhesion reaction. When theyaggregate platelets change from their discoid shape to a more sphericalform, they throw out long processes known as pseudopodia and somehowbecome sticky. The result of this is that they stick to one another andto the damaged tissue, thus plugging gaps or holes in the blood vesselwall. Endocannabinoids may control platelet activation and limitaggregate formation.

The phenomenon of aggregation is the most widely studied property ofplatelets: it is of interest not only for scientific reasons (plateletsmake an ideal test system for examining cellular mechanisms and drugaction), but also has diagnostic significance since there are manyconditions in which platelet function is abnormal.

The compounds or compositions as disclosed herein may be used to reduceplatelet aggregation in a subject suffering from many vaso-occlusivedisorders such as unstable angina, acute myocardial infarction,reocclusion of vessels following balloon angioplasty, transient ischemicattacks and strokes. Thrombocytosis or increased platelet count mayoccur in certain disease states such as cancer, chronic infections, andcertain blood diseases, and may cause increased blood clot formation orthrombosis due to platelet aggregation. The compounds of the presentinvention may be used to reduce platelet aggregation in various otherdiseases involving thrombosis, such as venous thrombosis, establishedperipheral arterial disease, thrombophlebitis, arterial embolism,coronary and cerebral arterial thrombosis, unstable angina, myocardialinfarction, stroke, cerebral embolism, renal embolism, pulmonaryembolism and other embolism- or thrombosis-related afflictions producedby but not limited to procedural or surgical interventions. Suchconditions may also result from thromboembolism and reocculsion duringand after thermbolytid therapy, after angioplasty, and after coronaryartery bypass.

The compounds or compositions as disclosed herein may be used to induceplatelet aggregation in a subject suffering from various bloodcoagulation disorders including, but not limited to, hemostaticdisorders characterized by prolonged bleeding times, thrombocytopenias,von Willebrand disease, hemophilia, myeloproliferative disorders (MPDs),myelodysplasia, paraproteinemias, and uremia In particular, conditionscan be treated which are caused by an impaired aggregation behavior ofblood platelets or thrombopathies, and bleeding conditions caused byplatelets deficiency (thrombocytopenia).

Anti-Angiogenic

Angiogenesis is an important biological process, necessary forreproduction, development, and wound repair. Angiogenesis begins withthe degradation of the basement membrane by proteases secreted fromactivated endothelial cells. In adults, the rate of proliferation ofendothelial cells is generally low, and tissues are normally in a stateof angiogenesis equilibrium in which growth factors that simulate newvessel growth are balanced by other factors which inhibit vessel growth.However, rapid proliferation of endothelial cells can occur duringcertain processes such as reproduction and wound healing. The rate ofangiogenesis responds to a change in the levels of angiogenic growthfactors.

Abnormal angiogenesis can occur in various diseases and disorders. Thesediseases and disorders can be divided into two groups: diseasesinvolving excessive angiogenesis, and diseases involving insufficientangiogenesis. In some diseases, decreased angiogenesis is beneficial dueto abnormal angiogenesis evidenced by the formation of abnormal bloodvessels, which are heterogeneous with regard to organization, unevenlydistributed, and chaotic. Abnormal blood vessels generally exhibit aserpentine or tortuous course, branch irregularly and formarterio-venous shunts, and may also be thin-walled and leaky. It istherefore desirable to be able to modulate the rate of angiogenesis inorder to help prevent or treat these types of conditions, either byincreasing or decreasing the rate of angiogenesis.

The compounds or compositions as disclosed herein may reduce cellmigration and proliferation and are thus useful in the treatment ofdiseases with overactive cell migration and proliferation, such asdisorders involving excessive angiogenesis. Provided herein are uses ofthe compounds or compositions for reducing angiogensis in a subject.Also provided are uses of the compounds or compositions in themanufacture of a medicament for reducing angiogenesis in a subject. Thedisclosed compounds and compositions may be used in various methodsincluding methods of reducing angiogenesis, comprising administering toa subject in need thereof a therapeutically effective amount of acompound of formula (I), or a pharmaceutically acceptable salt orpharmaceutical composition thereof.

The compounds or compositions as disclosed herein may be used fortreating diseases and disorders involving excessive angiogenesis,abnormal angiogenesis, or where decreased angiogenesis would bebeneficial, include retinal neovascularization, hemangioma, solidtumors, metastasis, psoriasis, neovascular glaucoma, diabeticretinopathy, macular degeneration, arthritis (e.g., rheumatoidarthritis), endometriosis, retinopathy of prematurity (ROP), gingivitis,and pre-eclampsia.

Prevention of solid tumor growth is of particular interest. Examples ofcancers that typically involve solid tumor growth include neoplasms ofthe central nervous system such as, but again not necessarily limited toglioblastomas, astrocytomas, neuroblastomas, meningiomas, ependymomas;cancers of hormone-dependent tissues such as prostate, testicles,uterus, cervix, ovary, mammary carcinomas including but not limited tocarcinoma in situ, medullary carcinoma, tubular carcinoma, invasive(infiltrating) carcinomas and mucinous carcinomas; melanomas, includingbut not limited to cutaneous and ocular melanomas; cancers of the lungwhich at least include squamous cell carcinoma, spindle carcinoma, smallcell carcinoma, adenocarcinoma and large cell carcinoma; and cancers ofthe gastrointestinal system such as esophageal, stomach, smallintestine, colon, colorectal, rectal and anal region which at leastinclude adenocarcinomas of the large bowel.

Vasoconstriction and Vasodilation

The compounds or compositions as disclosed herein may be used forinducing vasoconstriction or vasodilation in a subject. Also providedare uses of the compounds or compositions in the manufacture of amedicament for inducing vasoconstriction or vasodilation in a subject.The disclosed compounds or compositions as disclosed herein may be usedin a method of inducing vasoconstriction or vasodilation, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of a compound of formula (I), or a pharmaceutically acceptablesalt or pharmaceutical composition thereof.

The compounds or compositions as disclosed herein may modulate bloodflow through vasoconstriction and/or vasodilation. In some embodiments,the compounds or compositions may induce vasoconstriction.Vasoconstriction is the narrowing of the blood vessels resulting fromcontraction of the muscular wall of the vessels, in particular the largearteries and small arterioles. The process is particularly important instaunching hemorrhage and acute blood loss. The compounds andcompositions described herein may be used to treat shock, migraines, lowblood pressure, excess bleeding, and allergic reactions.

In some embodiments, the compounds or compositions as disclosed hereinmay induce vasodilation. Vasodilation is the widening of blood vesselsto increase blood flow in the body to tissues that need it. Thecompounds and compositions as disclosed herein may be used to treatconditions such as hypertension, wherein the subject has an abnormallyhigh blood pressure, as well as angina, congestive heart failure, anderectile dysfunction, diabetic nephropathy, Raynaud's syndrome,cardiomyopathy, and where maintaining a lower blood pressure reduces thesubject's risk of developing other cardiac problems. The compounds andcompositions as disclosed herein may be used prevent stroke, heartattacks, or heart failures.

5. EXAMPLES

General Synthesis of EDP-EAs and Derivatives.

Amide synthesis was performed in a two-step approach. First, anonspecific epoxidation reaction with 50 mg of docosahexaenoic acid(DHA) dissolved in 2 mL of dichloromethane (DCM) with 2 mol equiv ofmetachloroperoxybenzoic acid (mCPBA) was reacted for 1 h at roomtemperature. The reaction was stopped with an equal volume of 10%aqueous NaHCO₃ to remove mCPBA from the organic layer, and the aqueouslayer was re-extracted thrice with equal volumes of DCM; the combinedorganic layer was dried in vacuo. Purification of regioisomers wasachieved using normal-phase HPLC (NP-HPLC) using a Zorbax-NH₂semipreparative column (5 μm, 9.4×250 mm, Agilent, PN880952-208) with anisocratic gradient (hexane/isopropanol/acetic acid, 90:10:0.1) coupledto an HPLC system. For coeluting regioisomers of DHA-epoxides (19,20-EDPand 13,14-EDP), the mixtures were further purified on the same systemusing reverse-phase HPLC (RP-HPLC), a Sun Fire Prep C18 column (5 μm,19×50 mm, PN 186002566; Waters), a mobile system composed of solvent A(H₂O/acetonitrile/acetic acid, 95:5:0.1) and solvent B(H₂O/acetonitrile/acetic acid, 5:95:0.1), and a linear gradient from 50to 0% A in 50 min. The starting carboxylic acids prepared in thisfashion may be used to prepare various amide derivatives of theinvention.

Example 1. Synthesis of Amine EDP-EAs and Amino Terminal Derivatives

Scheme 1 shows a representative synthesis of amide modified derivatives.The purified epoxide isomer is reacted with the respective amine in thepresence of EDC and NHS to produce the coupled product with above 80/oconversion in all cases. This process may also be applied to thesynthesis of compounds having an epoxide at the 4,5, 7,8, 13,14, 16,17,or 19,20 positions.

(4Z,7Z)—N-Cyclopropyl-9-(3-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)oxiran-2-yl)nona-4,7-dienamide(10,11-EDP-CA)

To a solution of epoxide in acetonitrile, was added a solution of1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (10 mg/mL inacetonitrile) and N-hydroxysuccinimide (NHS) (10 mg/mL in acetonitrile)in the ratio of (1:50:50) and incubated at 37° C. for 20 mins. To thiswas added a solution of amine (2 mg/mL in acetonitrile) in the ratio of1:50 with epoxide and this was stirred at room temperature overnight.The acetonitrile was removed under reduced pressure and the residue wasdissolved in ethanol before purification via HPLC. Purification of10,11-EDP derivatives was performed using a reversed phasehigh-performance liquid chromatography (RP-HPLC), Sun Fire Prep C18 5 μm19×50 mm (Waters, PN 186002566) and a mobile system composed of solventA (H₂O/acetonitrile/acetic acid 95:5:0.1) and solvent B(H₂O/acetonitrile/acetic acid 5:95:0.1) and a linear gradient from 50% Ato 0% A in 50 minutes. ¹H NMR: δ 5.57-5.22 (m, 10H), 3.30-3.24 (t, 2H),3.24-3.14 (q, 2H), 2.99-2.93 (m, 1H), 2.87-2.77 (m, 6H), 2.73-2.66 (m,1H), 2.42-2.36 (m, 3H), 2.20-2.14 (t, 2H), 2.12-2.05 (t, 2H), 1.87-79(t, 2H), 1.00-0.92 (t, 3H), 0.88-0.84 (t, 3H); HR-ESI-MS (m/z) found:384.2910, [M+H]⁺ calculated C₂₅H₃₈NO₃: 383.58.

The following compounds were made using analogous procedures:

(4Z,7Z)—N-(3-Hydroxypropyl)-9-(3-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)oxiran-2-yl)nona-4,7-dienamide(10,11-EDP-NA)

Synthesis was performed as mentioned in the previous section using10,11-EDP and 3-amino-1-propanol. HR-ESI-MS (m/z) found [M+Na]:424.2891, [M+H]⁺ calculated C₂₅H₄₀NO₃: 401.29. ¹H NMR: δ 5.59-5.27 (m,10H), 3.88-2.79 (t, 1H), 3.75-3.69 (q, 2H), 3.66-3.59 (m, 2H), 3.45-3.38(m, 2H), 3.28-2.23 (t, 1H), 3.22-3.15 (m, 1H), 3.04-2.95 (m, 2H),2.91-2.72 (m, 4H), 2.67-2.63 (s, 1H), 2.62-2.58 (t, 1H), 2.48-2.40 (m,1H), 2.31-2.21 (m, 2H), 1.28-1.22 (m, 4H), 1.15-1.10 (t, 2H), 1.00-0.95(t, 2H).

(4Z,7Z)—N-(1-Hydroxypropan-2-yl)-9-(3-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)oxiran-2-yl)nona-4,7-dienamide(10,11-EDP-IA)

Synthesis was performed as mentioned in the previous section using10,11-EDP and R—(−)2-amino-1-propanol. HR-ESI-MS (m/z) found: 402.2901,[M+H]⁺ calculated C₂₅H₄₀NO₃: 401.29. ¹H NMR: δ 5.57-5.26 (m, 10H),4.16-3.98 (m, 3H), 3.71-3.57 (m, 2H), 3.57-3.44 (m, 3H), 3.09-2.98 (m,1H), 2.89-2.75 (m, 4H), 2.46-2.33 (m, 4H), 2.22-2.21 (m, 3H), 2.11-1.99(m, 2H), 0.99-0.94 (t, 3H), 0.89-0.85 (t, 3H).

Example 2. Synthesis of Aziridine Derivatives

Scheme 2A and 2B show representative conversions of epoxide to thecorresponding aziridine. The epoxide is first converted to azide withsodium azide and ammonium chloride and then reduced withtriphenylphosphine to produce the corresponding aziridine. This processmay also be applied to the synthesis of compounds having an aziridine atthe 4,5, 7,8, 13,14, 16,17, or 19,20 positions

To a stirred solution of sodium azide (2 equivalents) and ammoniumchloride (3 equivalents) in water at room temperature a solution ofethanolamine epoxide (1 equivalent) was added in MeOH and then thereaction was stirred at 80° C. for 3 h. After the solution is cooled toroom temperature, the excess of MeOH was removed under reduced pressureand the residue was diluted with EtOAc, washed with water, dried overanhydrous sodium sulfate and concentrated under reduced pressure to givea brown oil. Filtration on a pad of silica gel (hexane/EtOAc 4:1) gavethe nitrile that is taken forward for the next reaction. A solution ofnitrile in anhydrous acetonitrile was heated to reflux under nitrogenatmosphere. Next, triphenylphosphine (20 equivalents), was immediatelyadded and the reaction will be stirred under reflux for 3 h. Aftercooling to room temperature, the mixture was concentrated under reducedpressure and purified by column chromatography on silica gel(hexane/EtOAc 7:3).

Scheme 2B shows the synthesis of another representative aziridinederivative 19,20-EDP-EA aziridine, the mass spectrum for which is shownin FIG. 9.

Example 3. Synthesis of Thiirane Derivatives

Conversion of epoxide to corresponding thiirane in the presence ofpotassium thiocyanate and oxalic acid in a commercial microwave is shownSchemes 3A and 3B. This process may also be applied to the synthesis ofcompounds having a thiirane at the 4, 5, 7, 8, 13, 14, 16, 17, or 19, 20positions.

To a solution of amide derivative in methanol was added KSCN and oxalicacid and heated in a commercial microwave at power 1 for 10 mins. Thereaction mixture was cooled and concentrated in vacuo. The mixture waspurified using normal phase HPLC using 90% hexane 10% isopropanol as theeluent.

Scheme 3B shows the synthesis of another representative thiiranederivative 10,11-EDP-EA thiirane, the ¹H NMR spectrum for which is shownin FIG. 10.

Currently all 10,11 EDP derivatives at the amino end as well as thethiirane and 19,20-EDPEA thiirane and aziridine as described above havebeen synthesized and characterized ESI-MS and 1H-NMR. Furthermore,representative molecules were tested for their effect on apoptosis(Example 4) and migration using annexin V binding (Example 5) as well aswound healing assay. Additional studies were conducted to investigatethe receptor interactions of molecules 1-3 by using antagonists ofCannabinoid receptors 1 and 2 (rimonabant and AM 630, respectively) inboth Annexin V binding and wound healing assays. Hydrolyticsusceptibility of these molecules to fatty acid amide hydrolase (FAAH)were also tested using FAAH that is naturally expressed in pig brainmembranes.

Example 4. Apoptosis Assay

All three amino-modified derivatives of 10,11-EDP were tested for theirapoptotic activity using a BD biosciences Annexin V binding assay forapoptosis at 12.5 μM concentration (FIG. 2). Cells were grown andmaintained in Dulbecco's modified Eagle's medium supplemented with 10%fetal bovine serum, 1% streptomycin and penicillin at 37° C. in a 5% C₀₂humidified air atmosphere in 12 well plate to 90% confluency and thenappropriate amount of compound or control was added to the well. Thecells were incubated for 24 hours and then prepared for apoptosis assaysas indicated in BD biosciences Annexin V binding assay kit instructionsand analyzed by BD Accuri C6 flow cytometer and FCS flow software. Allthree compounds showed increased apoptotic potential as compared to theno treatment control. However, their effects were not consistent intrend among the three cell lines. The cyclopropyl analog seemed to havethe highest pro-apoptotic potential among the three within error limits.In osteosarcoma-derived cell-lines (HOS, MG63 and 143B cells), thecyclopropyl analog increased apoptosis to 27.19±4.05%, 17.09±4.4% and21.3±1.9%, respectively. The iso-propyl analog seemed to be the secondmost effective in HOS and MG63 cells with apoptotic potentials of20.15±1.75% and 17.48±2.8% respectively. In 143B cells the increase inpro-apoptotic potential was only 18.8±0.3% for the iso-propyl derivativeas compared to 25.7±0.4% for the n-propyl derivative. However, then-propyl derivative was least effective in HOS and MG63(osteosarcoma-derived) cells with only 17.05±1.4% and 15.15±3.28%respectively.

Example 5. Scratch Assay

A scratch assay was performed to analyze the anti-migratory propertiesof the three derivatives (FIGS. 3A-3C and 7). Cells were grown andmaintained in Dulbecco's modified Eagle's medium supplemented with 10%fetal bovine serum, 1% streptomycin and penicillin at 37° C. in a 5% C₀₂humidified air atmosphere in a 12 well plate to a confluent monolayerand then a scratch was made across the center and images were taken. Themedia was changed and appropriate compounds and controls were added andimages of the scratch were taken every 2 hours. The images wereprocessed by ImageJ software. In HOS cells (FIG. 3A), all 10,11-EDPderivatives restricted wound migration at 5 M concentration. While10-11-EDP-EA, the endogenous molecule, inhibited wound healing from1.00-1.44 times as compared to control over 10 hours, the10,11-cyclopropyl derivative shows significantly greater potency at the8 and 10 hour time points inhibiting migration by 4.5-6 times more thanvehicle control. The n-propyl and iso-propyl derivatives showed similarinhibition of wound migration as 10,11-EDP-EA with n-propyl restricting1-1.7 times migration and the iso-propyl restricting it 1-1.75 timesover 10 hours. In the 143B cells (FIG. 3B), restriction in woundmigration was 1-1.9 times by 10,11-EDP-EA, 1-1.47 times by n-propylderivative, 1-3.9 times by isopropyl derivative and 1 to nearly 10 foldby the cyclopropyl derivative as compared to the control. Finally, inthe MG63 cell line (FIG. 3C), the restriction in wound healing was 1-2times by 10,11-EDP-EA as compared to the control. The 10,11-EDP-NA and10,11-EDP-IA were slightly poorer than the control in restricting woundmigration. 10,11-EDP-CA was comparable to 10, 1-EDP-EA in the MG63 cellline in restricting cell migration. As observed from the variousresults, it was concluded that 10,11-EDP-CA was the most potent ininhibiting would healing in 143B and HOS cells and comparable to theparent molecule in MG63 cells.

Example 6. Anti-Inflammatory Assay in Microglial Cells

The anti-inflammatory effect of parent compounds was tested by measuringnitrite production in Bv2 microglial cells and the reduction inpro-inflammatory cytokine IL-6 (FIG. 4). Experiments were performed withmouse BV-2 microglial cells. Cells were grown and maintained inDulbecco's modified Eagle's medium supplemented with 10% fetal bovineserum, 1% streptomycin and penicillin at 37° C. in a 5% CO2 humidifiedair atmosphere. BV-2 cells were seeded in 24-well plates (200K cells/mL)and grown to 80-90% confluency. For regioisomer screening and doseresponse studies, media was replaced with serum-free media and the cellswere pre-incubated with the regioisomers for 4 hours prior tostimulation with 25 ng/mL LPS (Sigma-Aldrich, USA). Production of nitricoxide (NO) and cell toxicity and IL-6 production were measured. Allisomers of DHEA epoxides showed reduction in nitrate formation and dosedependently decreased IL-6 production.

Example 7. Presto-Tango -Arrestin Recruitment Assay

Binding of the parent compounds to putative receptors CNR1 and CNR2(cannabinoid receptors 1& 2) was measured by a Presto-Tango assay (FIG.5A and FIG. 5B). These receptors are responsible for many downstreameffects of marijuana derivatives as well as other endocannabinoids thathave been previously reported in literature and this study explores ifour compounds bind to these receptors. HTLA were received from the RothLab and CNR1 and CNR2 plasmids were purchased from Addgene. HTLA cellswere maintained in DMEM with 10% FBS containing 2 μg/mL of puromycin and100 μg/mL of hygromycin B at 37° C. in a 5% CO2 humidified airatmosphere and grown to 80-90% confluency. Cells were then seeded at20,000 cells per 100 uL into poly-L-lysine coated 96-well plate. After18-24 hrs, cells were transfected with CNR2 (0.1 ug/well) usingCalfectin as the transfection reagent. Transfection media was replacedafter 12-18 hours with serum-media and proceeded for −36 hours. On theday of the assay, serum-media was replaced with serum-free media for 4hours, then the compounds were added in a log dose manner in DMSO to afinal well volume of 200 uL and incubated overnight. The next day, mediawas removed and 20 μL of Bright-Glo solution was added to the cells andincubated for 20 min at room temperature in the dark and measured forluminescence. Relative luminescence units (RLU) values were normalizedto % receptor response, plotted as a function of compound concentrationand analyzed using “DoseResp” in OriginPro. The following EC₅₀ valueswere obtained for compounds described herein.

EC₅₀ (nM) EC₅₀ (nM) Compound CB1 CB2 CP 55 940 0.9 1.73 10,11 EDP-EA0.43 22.5 10,11 EDP-IA 0.07 0.08 10,11 EDP-NA 0.19 7.3 10,11 EDP-CA 0.030.46

Example 8. Susceptibility to FAAH Hydrolysis of 10, 11-DHEA Epoxides andits Amide Derivatives

Fatty acid amide hydrolase (FAAH) is a ubiquitously expressed protein invarious mammals and the sequence of the protein has shown to be highlyconserved in humans, mouse and pig. For our studies, we used pig brainmembrane preparations to analyze the effect of FAAH on 10,11-EDP-EA aswell as the three amino derived modifications. The preparation of pigforebrain membranes was achieved using dounce homogenization in buffer(50 mM Tris pH 7.4, 1 mM EDTA and 3 mM MgCl2) and membrane pelleting aspreviously described (Hillard, C. J.; Wilkison, D. M.; Edgemond, W. S.;Campbell, W. B. Characterization of the kinetics and distribution ofN-arachidonylethanolamine (anandamide) hydrolysis by rat brain. BiochimBiophys Acta 1995, 1257, 249-56). Incubations contained 5 μg forebrainprotein in a 0.5 mL reaction containing 50 mM Tris (pH 7.4), 1 mM EDTA,3 mM MgCl₂, and amide at 20 μM. At 40 min reactions were quenched withmethanol containing 1 mM PMSF and centrifuged to pellet protein (10,000g×10 min). The supernatant was collected and analyzed via LC-MS/MS asoutlined below.

The products of hydrolysis were measured by LC-MS/MS as indicated inmaterials and methods section. As observed from FIG. 6, there wassignificant reduction of hydrolytic potential in all the threederivatives as compared to 10,11-EDP-EA (p<0.01). While the rate ofhydrolysis of 10,11-EDP-EA to 10,11-EDP was 30.0±0.3 pmol min⁻¹ mgprotein⁻¹, the rate of hydrolysis for the derivatives—10,11-EDP-NA,10,11-EDP-IA and 10,11-EDP-CA was 0.09±0.01 pmol min⁻¹ mg protein⁻¹0.99±0.04 pmol min⁻¹ mg protein⁻¹ and 5.17±0.06 pmol min⁻¹ mg protein⁻¹respectively. For 19,20-EDP-EA, the rate is 150 pmol min⁻¹ mg protein⁻¹.Since the three derivatives show significantly reduced hydrolyticsusceptibility, they could have higher bioavailability and thus theirapoptotic and anti-migratory potential was further evaluated.

Example 9. 10,11-EDP-EA and its Analogs Prevent Angiogenesis in HUVECCells

Increased angiogenesis is one of the hallmarks of cancer. Thedevelopment of neo-vascularization is key for the adequate supply ofnutrients and oxygen to the site of metastasis. Endothelial tubeformation on matrix has been established as a cellular model forangiogenesis. Endothelial HUVEC cells form a networks of tubes whenplated on matrigel and the tube formation in presence and absence oftreatment can be quantified as a measure of restricted angiogenicpotential.

Angiogenesis in endothelial HUVEC cells was measured using abcamangiogenesis kit (ab204726). Briefly, HUVEC cells at passage 2 (p=2)were grown to 80% confluency. The matrigel provided was thawed overnightand 50 μL was put into each well of a 96 well plate that had beenchilled overnight in a −20° C. freezer. The plate was rocked slightlyand then allowed to incubate at 37° C. for 1 hour. 15,000 HUVEC cellswere then plated into the wells and were treated with vehicle control or0.5 t M or 1 μM compound. A no matrix control and a control withvinblastine (inhibitor of angiogenesis) was also performed. All wellswere performed in duplicates. The plates were then incubated for 5 hoursat 37° C. The incubation medium was removed and cells were washed with100 μL of wash buffer. 100 μL of staining dye was added to each well andincubated for 30 mins at 37° C. The wells were imaged using afluorescent microscope and analyzed using ImageJ with AngiogenesisAnalyzer Plugin. Endothelial HUVEC cells were grown on matrix andtreated with vehicle control, 0.5 μM compound or 1 μM compound. The tubeformation was assessed by Image J analysis. As seen in FIG. 8, 0.5 μMand 1 μM concentrations restrict tube formation significantly ascompared to the vehicle control.

For reasons of completeness, various aspects of the invention are setout in the following numbered clauses:

Clause 1. A compound of formula (I), or a pharmaceutically acceptablesalt thereof,

wherein,

one of L¹, L², L³, L⁴, L⁵, and L⁶ is

and the others of L¹, L², L³, L⁴, L⁵, and L⁶ are

is 3- to 6-membered ring containing at least one heteroatom selectedfrom the group consisting of oxygen, nitrogen, and sulfur;

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x1), -G¹, or—C₁₋₆alkylene-G¹;

G¹ is C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl, heteroaryl, orheterocycle, wherein G¹ is optionally substituted with 1, 2, 3, or 4R^(x1);

R² is C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x2), -G², or—C₁₋₆alkylene-G²;

G² is C₃₋₆-cycloalkyl, C₃₋₈cycloalkenyl, aryl, heteroaryl, orheterocycle, wherein G² is optionally substituted with 1, 2, 3, or 4R^(x2);

R^(x1) and R^(x2) at each occurrence are independently cyano, —OH,—OC₁₋₄alkyl, —OC(O)C₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl)₂,—NHC(O)C₁₋₄alkyl, or —N(C₁₋₄alkyl)C(O)C₁₋₄alkyl;

provided that R² is not —CH₂CH₂OH when

Clause 2. The compound of clause 1, or a pharmaceutically acceptablesalt thereof, wherein

Clause 3. The compound of any one of clauses 1-2, or a pharmaceuticallyacceptable salt thereof, wherein R¹ is hydrogen.

Clause 4. The compound of any one of clauses 1-3, or a pharmaceuticallyacceptable salt thereof, wherein R² is C₁₋₆alkyl, —C₁₋₆alkylene-R², -G²,or C₁₋₆alkylene-G².

Clause 5. The compound of any one of clauses 1-4, or a pharmaceuticallyacceptable salt thereof, wherein R² is —C₁₋₆alkylene-R^(x2).

Clause 6. The compound of any one of clauses 1-4, or a pharmaceuticallyacceptable salt thereof, wherein

R² is -G² or —C₁₋₆alkylene-G², and

G² is C₃₋₈cycloalkyl optionally substituted with 1, 2, 3, or 4 R^(x2).

Clause 7. The compound of clause 6, or a pharmaceutically acceptablesalt thereof, wherein G² is

which is optionally substituted with 1, 2, or 3R^(x2).

Clause 8. The compound of any one of clauses 1-7, or a pharmaceuticallyacceptable salt thereof, wherein R^(x2) at each occurrence isindependently —OH or —NH₂.

Clause 9. The compound of any one of clauses 1-7, or a pharmaceuticallyacceptable salt thereof, wherein R² is

Clause 10. The compound of clause 1, selected from the group consistingof

or a pharmaceutically acceptable salt thereof.

Clause 11. A pharmaceutical composition comprising a therapeuticallyeffective amount of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier.

Clause 12. The compound of any one of clause 1-10, or a pharmaceuticallyacceptable salt thereof, for use in treating cancer.

Clause 13. The compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for use in reducinginflammation in a subject.

Clause 14. The compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for use in reducing plateletaggregation in a subject.

Clause 15. The compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for use in reducingangiogenesis in a subject.

Clause 16. The compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for use in inducingvasoconstriction or vasodilation in a subject.

Clause 17. Use of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for manufacturing a medicamentfor treating cancer.

Clause 18. Use of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for manufacturing a medicamentfor reducing inflammation in a subject.

Clause 19. Use of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for manufacturing a medicamentfor reducing platelet aggregation in a subject.

Clause 20. Use of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for manufacturing a medicamentfor reducing angiogenesis in a subject.

Clause 21. Use of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, for manufacturing a medicamentfor inducing vasoconstriction or vasodilation in a subject.

Clause 22. A method of treating cancer comprising administering to asubject in need thereof a therapeutically effective amount of a compoundof any one of clauses 1-10, or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition of clause 11.

Clause 23. A method of reducing inflammation comprising administering toa subject in need thereof a therapeutically effective amount of acompound of any one of clauses 1-10, or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition of clause 11.

Clause 24. A method for reducing platelet aggregation comprisingadministering to a subject in need thereof a therapeutically effectiveamount of a compound of any one of clauses 1-10, or a pharmaceuticallyacceptable salt thereof, or a pharmaceutical composition of clause 11.

Clause 25. A method of reducing angiogenesis comprising administering toa subject in need thereof a therapeutically effective amount of acompound of any one of clauses 1-10, or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition of clause 11.

Clause 26. A method of inducing vasoconstriction or vasodilationcomprising administering to a subject in need thereof a therapeuticallyeffective amount of a compound of any one of clauses 1-10, or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of clause 11.

REFERENCES

-   1. (R)-Methanandamide—a Chiral Novel Anandamide Possessing Higher    Potency and Metabolic Stability. Abadji, V., Lin, S. Y., Taha, G.,    Griffin, G., Stevenson, L. A., Pertwee, R. G., and Makriyannis, A. J    Med Chem, 1994, 37, 1889-   2. Structure-activity relationships among N-arachidonylethanolamine    (anandamide) head group analogues for the anandamide transporter.    Jarrahian, A., Manna, S., Edgemond, W. S., Campbell, W. B., and    Hillard, C. J. J Neurochem, 2000, 74, 2597-   3. Cannabinoid Receptor-Binding and Agonist Activity of Amides and    Esters of Arachidonic-Acid. Pinto, J. C., Potie, F., Rice, K. C.,    Boring, D., Johnson, M. R., Evans, D. M., Wilken, G. H.,    Cantrell, C. H., and Howlett, A. C. Mol Pharmacol, 1994, 46, 516-   4. Structural requirements for binding of anandamide-type compounds    to the brain cannabinoid receptor. Sheskin, T., Hanus, L., Slager,    J., Vogel, Z., and Mechoulam, R. J Med Chem, 1997, 40, 659-   5. Arachidonate epoxygenase: inhibitors and metabolite analogues. J.    R Falck, Sukumar Manna, Jacques Viala, Arup K. Siddhanta,    Christine A. Moustakis, and Jorge Capdevila. Tet Lett 1985, 26,    2287.

The invention claimed is:
 1. A compound of formula (I), or apharmaceutically acceptable salt thereof,

wherein, one of L¹, L², L³, L⁴, L⁵, and L⁶ is

and the others of L¹, L², L³, L⁴, L⁵, and L⁶ are

is 3- to 6-membered ring containing at least one heteroatom selectedfrom the group consisting of oxygen, nitrogen, and sulfur; R¹ ishydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x1), -G¹, or—C₁₋₆alkylene-G¹; G¹ is C₃₋₈-cycloalkyl, C₃₋₈cycloalkenyl, aryl,heteroaryl, or heterocycle, wherein G¹ is optionally substituted with 1,2, 3, or 4 R^(x1); R² is C₁₋₆alkyl, C₁₋₆haloalkyl, —C₁₋₆alkylene-R^(x2),-G², or —C₁₋₆alkylene-G²; G² is C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl,heteroaryl, or heterocycle, wherein G² is optionally substituted with 1,2, 3, or 4 R^(x2); R^(x1) and R^(x2) at each occurrence areindependently cyano, —OH, —OC₁₋₄alkyl, —OC(O)C₁₋₄alkyl, —NH₂,—NHC₁₋₄alkyl, —N(C₁₋₄alkyl)₂, —NHC(O)C₁₋₄alkyl, or—N(C₁₋₄alkyl)C(O)C₁₋₄-alkyl; provided that R² is not —CH₂CH₂OH when


2. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein


3. The compound of any one of claims 1-2, or a pharmaceuticallyacceptable salt thereof, wherein R¹ is hydrogen.
 4. The compound of anyone of claims 1-3, or a pharmaceutically acceptable salt thereof,wherein R² is C₁₋₆alkyl, —C₁₋₆alkylene-R^(x2), -G, or —C₁₋₆alkylene-G².5. The compound of any one of claims 1-4, or a pharmaceuticallyacceptable salt thereof, wherein R² is —C₁₋₆alkylene-R^(x2).
 6. Thecompound of any one of claims 1-4, or a pharmaceutically acceptable saltthereof, wherein R² is -G² or —C₁₋₆alkylene-G², and G² is C₃₋₈cycloalkyloptionally substituted with 1, 2, 3, or 4 R^(x2).
 7. The compound ofclaim 6, or a pharmaceutically acceptable salt thereof, wherein G² is

which is optionally substituted with 1, 2, or 3R^(x2).
 8. The compoundof any one of claims 1-7, or a pharmaceutically acceptable salt thereof,wherein R² at each occurrence is independently —OH or —NH₂.
 9. Thecompound of any one of claims 1-7, or a pharmaceutically acceptable saltthereof, wherein R² is


10. The compound of claim 1, selected from the group consisting of

or a pharmaceutically acceptable salt thereof.
 11. A pharmaceuticalcomposition comprising a therapeutically effective amount of a compoundof any one of claims 1-10, or a pharmaceutically acceptable saltthereof, and a pharmaceutically acceptable carrier.
 12. The compound ofany one of claims 1-10, or a pharmaceutically acceptable salt thereof,for use in treating cancer.
 13. The compound of any one of claims 1-10,or a pharmaceutically acceptable salt thereof, for use in reducinginflammation in a subject.
 14. The compound of any one of claims 1-10,or a pharmaceutically acceptable salt thereof, for use in reducingplatelet aggregation in a subject.
 15. The compound of any one of claims1-10, or a pharmaceutically acceptable salt thereof, for use in reducingangiogenesis in a subject.
 16. The compound of any one of claims 1-10,or a pharmaceutically acceptable salt thereof, for use in inducingvasoconstriction or vasodilation in a subject.
 17. Use of a compound ofany one of claims 1-10, or a pharmaceutically acceptable salt thereof,for manufacturing a medicament for treating cancer.
 18. Use of acompound of any one of claims 1-10, or a pharmaceutically acceptablesalt thereof, for manufacturing a medicament for reducing inflammationin a subject.
 19. Use of a compound of any one of claims 1-10, or apharmaceutically acceptable salt thereof, for manufacturing a medicamentfor reducing platelet aggregation in a subject.
 20. Use of a compound ofany one of claims 1-10, or a pharmaceutically acceptable salt thereof,for manufacturing a medicament for reducing angiogenesis in a subject.21. Use of a compound of any one of claims 1-10, or a pharmaceuticallyacceptable salt thereof, for manufacturing a medicament for inducingvasoconstriction or vasodilation in a subject.
 22. A method of treatingcancer comprising administering to a subject in need thereof atherapeutically effective amount of a compound of any one of claims1-10, or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of claim
 11. 23. A method of reducing inflammationcomprising administering to a subject in need thereof a therapeuticallyeffective amount of a compound of any one of claims 1-10, or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of claim
 11. 24. A method for reducing platelet aggregationcomprising administering to a subject in need thereof a therapeuticallyeffective amount of a compound of any one of claims 1-10, or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of claim
 11. 25. A method of reducing angiogenesiscomprising administering to a subject in need thereof a therapeuticallyeffective amount of a compound of any one of claims 1-10, or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of claim
 11. 26. A method of inducing vasoconstriction orvasodilation comprising administering to a subject in need thereof atherapeutically effective amount of a compound of any one of claims1-10, or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of claim 11.